Author Interviews, Heart Disease, Psychological Science / 11.02.2020
Two Common Drugs May Reduce Risk of Heart Attack During Grief
MedicalResearch.com Interview with:
[caption id="attachment_53123" align="alignleft" width="125"]
Prof. Tofler[/caption]
Prof. Geoffrey Tofler MBBS MB FRACP FACC
Professor of Preventative Cardiology, University of Sydney
Senior Staff Cardiologist, Royal North Shore Hospital
New South Wales, Australia
MedicalResearch.com: What is the background for this study?
Response: Bereavement due to the death of a loved one is one of the most stressful experiences to which almost every human is exposed. Grief is an unavoidable and natural reaction to the loss. While in most people the grief reaction gradually diminishes, an increased risk of heart attack or has been described in the early weeks and months following bereavement. Although this increase in heart attacks is well recognised, until now there have not been any previous studies to provide guidance on how to safely reduce the risk.
Prof. Tofler[/caption]
Prof. Geoffrey Tofler MBBS MB FRACP FACC
Professor of Preventative Cardiology, University of Sydney
Senior Staff Cardiologist, Royal North Shore Hospital
New South Wales, Australia
MedicalResearch.com: What is the background for this study?
Response: Bereavement due to the death of a loved one is one of the most stressful experiences to which almost every human is exposed. Grief is an unavoidable and natural reaction to the loss. While in most people the grief reaction gradually diminishes, an increased risk of heart attack or has been described in the early weeks and months following bereavement. Although this increase in heart attacks is well recognised, until now there have not been any previous studies to provide guidance on how to safely reduce the risk.

Deborah M Eaton
Doctorate Student / Research Assistant
Temple University
MedicalResearch.com: What is the background for this study?
Response: Heart failure (HF) with preserved ejection fraction (HFpEF) accounts for approximately 50% of cases of HF and to date clinical trials with HFpEF patients have failed to produce positive outcomes. Part of this is likely due to the lack of HFpEF animal models for preclinical testing. Our lab addressed this gap in knowledge by developing an animal model that mimics critical features of the human HFpEF phenotype. We performed an in-depth cardiopulmonary characterization highlighting that the model has characteristics of human disease. We then tested the effects of a pan-HDAC inhibitor, vorinostat/SAHA, in collaboration with Dr. Timothy McKinsey, who is an expert in HDAC inhibitors and recently published work1 that laid the foundation for this study.


Dr. Hongying (Daisy) Dai[/caption]
Hongying (Daisy) Dai, PhD
Associate Professor
Department of Biostatistics | College of Public Health
University of Nebraska Medical Center
Omaha, NE
MedicalResearch.com: What is the background for this study?
Response: E-cigarette use increased dramatically from 11.7% to 27.5% for high school students and from 3.3% to 10.5% for middle school students during the periods of 2017 - 2019. In September 2018, the Food and Drug Administration (FDA) warned that youth e-cigarette use is reaching an epidemic proportion.
Exposure to secondhand aerosol (SHA) from e-cigarettes is not harmless as e-cigarettes aerosol contains nicotine and potentially harmful substances, including carbonyl compounds, TSNAs, heavy metals, and glycols. This study analyzed the 2015-2018 National Youth Tobacco Survey (NYTS) and the main findings are:
Prof. Woloshin[/caption]
Steven Woloshin, MD, MS
Professor of Medicine and Community and Family Medicine
Professor, The Dartmouth Institute for Health Policy and Clinical Practice
MedicalResearch.com: What is the background for this study?
Response: Industry spends more on detailing visits and free samples than any other form of prescription drug marketing. There is good evidence that these activities can lead to more use of expensive new drugs over equally effective cheaper options. Given these concerns there have been efforts by some hospitalls and practices to restrict these forms of marketing.
We asked physicians in group practices delivering primary care about how often pharmaceutical reps visit their practice and whether they have a free sample closet.